Utilization management programs for atopic dermatitis may hinder patient care, causing treatment delays and increased costs despite advances in biologic therapies.
Joseph Biskupiak, PhD, MBA
Advertisement
Articles by Joseph Biskupiak, PhD, MBA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts Galderma’s BLA Resubmission for Liquid Neuromodulator RelabotulinumtoxinA
2
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
3
Introducing Dermatology Times NP/PA Connect
4
Icotrokinra Shows Superior Efficacy Over Advanced Oral Therapies in New Psoriasis Meta-Analysis
5